VEGFA Human Gene Knockout Kit (CRISPR)
$1,657.00
4 Weeks*
Specifications
| Product Data | |
| Format | 2 gRNA vectors, 1 GFP-puro donor, 1 scramble control |
|---|---|
| Vector | GFP-puro |
| Target Symbol | VEGFA |
| Locus ID | 7422 |
| Components |
KN217312G1, VEGFA gRNA vector 1 in pCas-Guide CRISPR vector, Target Sequence: CCCAGCTACCACCTCCTCCC KN217312G2, VEGFA gRNA vector 2 in pCas-Guide CRISPR vector, Target Sequence: TCCACTGTCCGCCGCCGGCC KN217312D, donor DNA containing left and right homologous arms and GFP-puro functional cassette. Homologous arm and GFP-puro sequences: pUC vector backbone in gray; Left arm sequence in blue; GFP-puro in green; Right arm in violet GATCGTTGGG AACCGGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA CACCACGATG CCTGTAGCAA TGGCAACAAC GTTGCGCAAA CTATTAACTG GCGAACTACT TACTCTAGCT TCCCGGCAAC AATTAATAGA CTGGATGGAG GCGGATAAAG TTGCAGGACC ACTTCTGCGC TCGGCCCTTC CGGCTGGCTG GTTTATTGCT GATAAATCTG GAGCCGGTGA GCGTGGTTCT CGCGGTATCA TTGCAGCACT GGGGCCAGAT GGTAAGCCCT CCCGTATCGT AGTTATCTAC ACGACGGGGA GTCAGGCAAC TATGGATGAA CGAAATAGAC AGATCGCTGA GATAGGTGCC TCACTGATTA AGCATTGGTA ACTGTCAGAC CAAGTTTACT CATATATACT TTAGATTGAT TTAAAACTTC ATTTTTAATT TAAAAGGATC TAGGTGAAGA TCCTTTTTGA TAATCTCATG ACCAAAATCC CTTAACGTGA GTTTTCGTTC CACTGAGCGT CAGACCCCGT AGAAAAGATC AAAGGATCTT CTTGAGATCC TTTTTTTCTG CGCGTAATCT GCTGCTTGCA AACAAAAAAA CCACCGCTAC CAGCGGTGGT TTGTTTGCCG GATCAAGAGC TACCAACTCT TTTTCCGAAG GTAACTGGCT TCAGCAGAGC GCAGATACCA AATACTGTTC TTCTAGTGTA GCCGTAGTTA GGCCACCACT TCAAGAACTC TGTAGCACCG CCTACATACC TCGCTCTGCT AATCCTGTTA CCAGTGGCTG CTGCCAGTGG CGATAAGTCG TGTCTTACCG GGTTGGACTC AAGACGATAG TTACCGGATA AGGCGCAGCG GTCGGGCTGA ACGGGGGGTT CGTGCACACA GCCCAGCTTG GAGCGAACGA CCTACACCGA ACTGAGATAC CTACAGCGTG AGCTATGAGA AAGCGCCACG CTTCCCGAAG GGAGAAAGGC GGACAGGTAT CCGGTAAGCG GCAGGGTCGG AACAGGAGAG CGCACGAGGG AGCTTCCAGG GGGAAACGCC TGGTATCTTT ATAGTCCTGT CGGGTTTCGC CACCTCTGAC TTGAGCGTCG ATTTTTGTGA TGCTCGTCAG GGGGGCGGAG CCTATGGAAA AACGCCAGCA ACGCGGCCTT TTTACGGTTC CTGGCCTTTT GCTGGCCTTT TGCTCACATG TTCTTTCCTG CGTTATCCCC TGATTCTGTG GATAACCGTA TTACCGCCTT TGAGTGAGCT GATACCGCTC GCCGCAGCCG AACGACCGAG CGCAGCGAGT CAGTGAGCGA GGAAGCGGAA GAGCGCCCAA TACGCAAACC GCCTCTCCCC GCGCGTTGGC CGATTCATTA ATGCAGCTGG CACGACAGGT TTCCCGACTG GAAAGCGGGC AGTGAGCGCA ACGCAATTAA TGTGAGTTAG CTCACTCATT AGGCACCCCA GGCTTTACAC TTTATGCTTC CGGCTCGTAT GTTGTGTGGA ATTGTGAGCG GATAACAATT TCACACAGGA AACAGCTATG ACCATGATTA CGCCAAGCTC CTTCCTCTTC CAGCCCTTCC TCTTTCACTG ACTGACTGAC TGGAAGACAC ACCTTTAAAA GTCGGCTGGT AGCGGGGAGG ATCGCGGAGG CTTGGGGCAG CCGGGTAGCT CGGAGGTCGT GGCGCTGGGG GCTAGCACCA GCGCTCTGTC GGGAGGCGCA GCGGTTAGGT GGACCGGTCA GCGGACTCAC CGGCCAGGGC GCTCGGTGCT GGAATTTGAT ATTCATTGAT CCGGGTTTTA TCCCTCTTCT TTTTTCTTAA ACATTTTTTT TTAAAACTGT ATTGTTTCTC GTTTTAATTT ATTTTTGCTT GCCATTCCCC ACTTGAATCG GGCCGACGGC TTGGGGAGAT TGCTCTACTT CCCCAAATCA CTGTGGATTT TGGAAACCAG CAGAAAGAGG AAAGAGGTAG CAAGAGCTCC AGAGAGAAGT CGAGGAAGAG AGAGACGGGG TCAGAGAGAG CGCGCGGGCG TGCGAGCAGC GAAAGCGACA GGGGCAAAGT GAGTGACCTG CTTTTGGGGG TGACCGCCGG AGCGCGGCGT GAGCCCTCCC CCTTGGGATC CCGCAGCTGA CCAGTCGCGA CTAGCATGGA GAGCGACGAG AGCGGCCTGC CCGCCATGGA GATCGAGTGC CGCATCACCG GCACCCTGAA CGGCGTGGAG TTCGAGCTGG TGGGCGGCGG AGAGGGCACC CCCGAGCAGG GCCGCATGAC CAACAAGATG AAGAGCACCA AAGGCGCCCT GACCTTCAGC CCCTACCTGC TGAGCCACGT GATGGGCTAC GGCTTCTACC ACTTCGGCAC CTACCCCAGC GGCTACGAGA ACCCCTTCCT GCACGCCATC AACAACGGCG GCTACACCAA CACCCGCATC GAGAAGTACG AGGACGGCGG CGTGCTGCAC GTGAGCTTCA GCTACCGCTA CGAGGCCGGC CGCGTGATCG GCGACTTCAA GGTGATGGGC ACCGGCTTCC CCGAGGACAG CGTGATCTTC ACCGACAAGA TCATCCGCAG CAACGCCACC GTGGAGCACC TGCACCCCAT GGGCGATAAC GATCTGGATG GCAGCTTCAC CCGCACCTTC AGCCTGCGCG ACGGCGGCTA CTACAGCTCC GTGGTGGACA GCCACATGCA CTTCAAGAGC GCCATCCACC CCAGCATCCT GCAGAACGGG GGCCCCATGT TCGCCTTCCG CCGCGTGGAG GAGGATCACA GCAACACCGA GCTGGGCATC GTGGAGTACC AGCACGCCTT CAAGACCCCG GATGCAGATG CCGGTGAAGA AAGAGTTTAA GAATTCCGAT CATATTCAAT AACCCTTAAT ATAACTTCGT ATAATGTATG CTATACGAAG TTATTAGGTC TGAAGAGGAG TTTACGTCCA GCCAAGCTTA GGATCTCGAC CTCGAAATTC TACCGGGTAG GGGAGGCGCT TTTCCCAAGG CAGTCTGGAG CATGCGCTTT AGCAGCCCCG CTGGGCACTT GGCGCTACAC AAGTGGCCTC TGGCCTCGCA CACATTCCAC ATCCACCGGT AGGCGCCAAC CGACTCCGTT CTTTGGTGGC CCCTTCGCGC CACCTTCTAC TCCTCCCCTA GTCAGGAAGT TCCCCCCCGC CCCGCAGCTC GCGTCGTGCA GGACGTGACA AATGGAAGTA GCACGTCTCA CTAGTCTCGT GCAGATGGAC AGCACCGCTG AGCAATGGAA GCGGGTAGGC CTTTGGGGCA GCGGCCAATA GCAGCTTTGC TCCTTCGCTT TCTGGGCTCA GAGGCTGGGA AGGGGTGGGT CCGGGGGCGG GCTCAGGGGC GGGCTCAGGG GCGGGGCGGG CGCCCGAAGG TCCTCCGGAG GCCCGGCATT CTGCACGCTT CAAAAGCGCA CGTCTGCCGC GCTGTTCTCC TCTTCCTCAT CTCCGGGCCT TTCGACCTGC ATCCATCTAG ATCTCGAGCA GCTGAAGCTT ACCATGACCG AGTACAAGCC CACGGTGCGC CTCGCCACCC GCGACGACGT CCCCAGGGCC GTACGCACCC TCGCCGCCGC GTTCGCCGAC TACCCCGCCA CGCGCCACAC CGTCGATCCG GACCGCCACA TCGAGCGGGT CACCGAGCTG CAAGAACTCT TCCTCACGCG CGTCGGGCTC GACATCGGCA AGGTGTGGGT CGCGGACGAC GGCGCCGCGG TGGCGGTCTG GACCACGCCG GAGAGCGTCG AAGCGGGGGC GGTGTTCGCC GAGATCGGCC CGCGCATGGC CGAGTTGAGC GGTTCCCGGC TGGCCGCGCA GCAACAGATG GAAGGCCTCC TGGCGCCGCA CCGGCCCAAG GAGCCCGCGT GGTTCCTGGC CACCGTCGGC GTCTCGCCCG ACCACCAGGG CAAGGGTCTG GGCAGCGCCG TCGTGCTCCC CGGAGTGGAG GCGGCCGAGC GCGCCGGGGT GCCCGCCTTC CTGGAGACCT CCGCGCCCCA CAACCTCCCC TTCTACGAGC GGCTCGGCTT CACCGTCACC GCCGACGTCG AGGTGCCCGA AGGACCGCGC ACCTGGTGCA TGACCCGCAA GCCCGGTGCC TGACGCCCGC CCCACGACCC GCAGCGCCCG ACCGAAAGGA GCGCACGACC CCATGCATCG ATGATATCAG ATCCCCGGGA TGCAGAAATT GATGATCTAT TAAACAATAA AGATGTCCAC TAAAATGGAA GTTTTTCCTG TCATACTTTG TTAAGAAGGG TGAGAACAGA GTACCTACAT TTTGAATGGA AGGATTGGAG CTACGGGGGT GGGGGTGGGG TGGGATTAGA TAAATGCCTG CTCTTTACTG AAGGCTCTTT ACTATTGCTT TATGATAATG TTTCATAGTT GGATATCATA ATTTAAACAA GCAAAACCAA ATTAAGGGCC AGCTCATTCC TCCCACTCAT GATCTATAGA TCTATAGATC TCTCGTGGGA TCATTGTTTT TCTCTTGATT CCCACTTTGT GGTTCTAAGT ACTGTGGTTT CCAAATGTGT CAGTTTCATA GCCTGAAGAA CGAGATCAGC AGCCTCTGTT CCACATACAC TTCATTCTCA GTATTGTTTT GCCAAGTTCT AATTCCATCA GAAGCTGGTC GAGATCCGGA ACCCTTAATA TAACTTCGTA TAATGTATGC TATACGAAGT TATTAGGTCC CTCGAAGAGG TTCACTAGGC GCGCCAGCCG CGGGCAGGGG CCGGAGCCCG CGCCCGGAGG CGGGGTGGAG GGGGTCGGGG CTCGCGGCGT CGCACTGAAA CTTTTCGTCC AACTTCTGGG CTGTTCTCGC TTCGGAGGAG CCGTGGTCCG CGCGGGGGAA GCCGAGCCGA GCGGAGCCGC GAGAAGTGCT AGCTCGGGCC GGGAGGAGCC GCAGCCGGAG GAGGGGGAGG AGGAAGAAGA GAAGGAAGAG GAGAGGGGGC CGCAGTGGCG ACTCGGCGCT CGGAAGCCGG GCTCATGGAC GGGTGAGGCG GCGGTGTGCG CAGACAGTGC TCCAGCCGCG CGCGCTCCCC AGGCCCTGGC CCGGGCCTCG GGCCGGGGAG GAAGAGTAGC TCGCCGAGGC GCCGAGGAGA GCGGGCCGCC CCACAGCCCG AGCCGGAGAG GGAGCGCGAG CCGCGCCGGC CCCGGTCGGG CCTCCGAAAC CATGAACTTT CTGCTGTCTT GGGTGCATTG GAGCCTTGCC TTGCTGCTCT ACCTCCACCA TGCCAAGGTA AGCGGTCGTG CCCTGCTGGC GCCGCGGGCC GCTGCGAGCG CCTCTCCCGG CTGGGGACGT GCGTGCGAGC GCGCGAGCAC AGTCTTCACT GACTGACTGA CTGGAAAGTC CTCTCCACTG ACTGTAGCCT CCAATTCACT GGCCGTCGTT TTACAACGTC GTGACTGGGA AAACCCTGGC GTTACCCAAC TTAATCGCCT TGCAGCACAT CCCCCTTTCG CCAGCTGGCG TAATAGCGAA GAGGCCCGCA CCGATCGCCC TTCCCAACAG TTGCGCAGCC TGAATGGCGA ATGGCGCCTG ATGCGGTATT TTCTCCTTAC GCATCTGTGC GGTATTTCAC ACCGCATACG TCAAAGCAAC CATAGTACGC GCCCTGTAGC GGCGCATTAA GCGCGGCGGG TGTGGTGGTT ACGCGCAGCG TGACCGCTAC ACTTGCCAGC GCCCTAGCGC CCGCTCCTTT CGCTTTCTTC CCTTCCTTTC TCGCCACGTT CGCCGGCTTT CCCCGTCAAG CTCTAAATCG GGGGCTCCCT TTAGGGTTCC GATTTAGTGC TTTACGGCAC CTCGACCCCA AAAAACTTGA TTTGGGTGAT GGTTCACGTA GTGGGCCATC GCCCTGATAG ACGGTTTTTC GCCCTTTGAC GTTGGAGTCC ACGTTCTTTA ATAGTGGACT CTTGTTCCAA ACTGGAACAA CACTCAACCC TATCTCGGGC TATTCTTTTG ATTTATAAGG GATTTTGCCG ATTTCGGCCT ATTGGTTAAA AAATGAGCTG ATTTAACAAA AATTTAACGC GAATTTTAAC AAAATATTAA CGTTTACAAT TTTATGGTGC ACTCTCAGTA CAATCTGCTC TGATGCCGCA TAGTTAAGCC AGCCCCGACA CCCGCCAACA CCCGCTGACG CGCCCTGACG GGCTTGTCTG CTCCCGGCAT CCGCTTACAG ACAAGCTGTG ACCGTCAACG GGAGCTGCAT GTGTCAGAGG TTTTCACCGT CATCACCGAA ACGCGCGACC CGAAAGGGCC TCGTGATACG CCTATTTTTA TAGGTTAATG TCATGATAAT AATGGTTTCT TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTG TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT GCTTCAATAA TATTGAAAAA GGAAGAGTAT GAGTATTCAA CATTTCCGTG TCGCCCTTAT TCCCTTTTTT GCGGCATTTT GCCTTCCTGT TTTTGCTCAC CCAGAAACGC TGGTGAAAGT AAAAGATGCT GAAGATCAGT TGGGTGCACG AGTGGGTTAC ATCGAACTGG ATCTCAACAG CGGTAAGATC CTTGAGAGTT TTCGCCCCGA AGAACGTTTT CCAATGATGA GCACTTTTAA AGTTCTGCTA TGTGGCGCGG TATTATCCCG TATTGACGCC GGGCAAGAGC AACTCGGTCG CCGCATACAC TATTCTCAGA ATGACTTGGT TGAGTACTCA CCAGTCACAG AAAAGCATCT TACGGATGGC ATGACAGTAA GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC TGCGGCCAAC TTACTTCTGA CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA CAACATGGGG GATCATGTAA CTCGCCTTGE100003, scramble sequence in pCas-Guide vector |
| OTI Disclaimer | These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process. |
| Reference Data | |
| RefSeq | NM_001025366, NM_001025367, NM_001025368, NM_001025369, NM_001025370, NM_001033756, NM_001171622, NM_001171623, NM_001171624, NM_001171625, NM_001171626, NM_001171627, NM_001171628, NM_001171629, NM_001171630, NM_001204384, NM_001204385, NM_001287044, NM_003376, NM_001317010 |
| UniProt ID | P15692 |
| Synonyms | MVCD1; VEGF; VPF |
| Summary | This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines. provided by RefSeq, Jun 2020 |
| Shipping | Ambient |
Reviews
Documents
| Product Manuals |
| FAQs |
| SDS |
Resources
Other Versions
| SKU | Description | Size | Price | |
|---|---|---|---|---|
| GA105115 | VEGFA CRISPRa kit - CRISPR gene activation of human vascular endothelial growth factor A | 1 kit |
$1,657.00
|
|
| KN217312BN | VEGFA - human gene knockout kit via CRISPR, HDR mediated | 1 kit |
$1,657.00
|
|
| KN217312LP | VEGFA - human gene knockout kit via CRISPR, HDR mediated | 1 kit |
$1,657.00
|
|
| KN217312RB | VEGFA - human gene knockout kit via CRISPR, HDR mediated | 1 kit |
$1,657.00
|
|
| KN417312 | VEGFA - KN2.0, Human gene knockout kit via CRISPR, non-homology mediated. | 1 kit |
$1,657.00
|
|
Citations
Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake
Ko, Lee, Kenny et al
Commun Biol (2019) 2, 386 DOI: 10.1038/s42003-019-0609-x
Ko, Lee, Kenny et al
Commun Biol (2019) 2, 386 DOI: 10.1038/s42003-019-0609-x
AI Summary: OriGene’s human VEGFA gene knockout kit was used to generate VEGFA-deficient, GFP-expressing ES2 cell lines via CRISPR/Cas9 gene editing, enabling the study of VEGF’s role in cancer-derived extracellular vesicle-mediated angiogenesis.
Snippet: GFP-expressing ES2 VEGF−/− cells were generated in this study by CRISPR/Cas9 gene editing using the human VEGFA gene knockout kit (Origene). Briefly, ES2 cells were co-transfected with VEGFA sgRNA plasmid and donor vector that contains predesigned homologous sequences flanking the GFP and puromycin resistance selection cassette. Individual clones, derived from single GFP-expressing cells, were sel...
Showing 1-1 of 1 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen
complexities in the preparation of your product. International customers may expect an additional 1-2 weeks
in shipping.
Related Products
- Price:
- Actual Price:
Welcome to OriGene AI!
I'm your AI-powered guide to everything OriGene.
Ask me anything:
- Product specs
- Ordering help
- Technical questions
- How to find exactly what your experiment needs
Prefer a live agent? Connect with us by clicking the green chat icon, as seen in the image below or email our team at custsupport@origene.com.
